ARTICLE | Finance
Kyndred spirits
Why Atlas, OrbiMed created a separate company for immunometabolism asset ARY-007
December 15, 2017 9:28 PM UTC
Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the door open for different funding strategies as their programs mature.
On Dec. 14, Arrys raised a $21 million series A round and Kyn emerged from stealth mode armed with $28 million it raised in a series A round last year. Atlas Venture and OrbiMed Advisors participated in both rounds. Atlas entrepreneur-in-residence Mark Manfredi is president and CEO of Kyn and OrbiMed venture partner Iain Dukes is president and CEO of Arrys. ...